NKT2152

PreclinicalSmall molecule

NNiKang Therapeutics, Inc.

NKT2152 is one of 9 small molecule programs targeting Advanced Liver Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Liver CancersActive, not recruiting

Advanced Liver CancersPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Advanced Liver Cancers

#DrugCompanyPhaseTrials

Avastin

Roche

Preclinical

1 2

Tecentriq

Roche

Preclinical

1 3

Actemra

CCelltrion

Preclinical

1 4

Tiragolumab

Roche

Preclinical

1 5

ADG126

Sanofi

Preclinical

1 6

Tobemstomig

Roche

Preclinical

1 7

TPST-1120

Roche

Preclinical

1 8

NKT2152

NNiKang Therapeutics, Inc.

Preclinical

1 9

IO-108

IImmune-Onc Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Advanced Liver Cancers

NCT04524871

Clinical

Trials by Indication[1]

Renal Cell Carcinoma2 trials

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Terminated·NNiKang Therapeutics, Inc.·Phase 1/2·NCT05119335·120 enrolled

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Terminated·NNiKang Therapeutics, Inc.·Phase 2·NCT05935748·18 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NKT2152. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NKT2152 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NKT2152. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NiKang Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNiKang Therapeutics, Inc.

NKT2152

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Renal Cell Carcinoma2 trials

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News